LSPG(SZ:301111)2025-10-29 11:40Financial Performance - The company's revenue for Q3 2025 was ¥73,634,583.96, a decrease of 3.58% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥904,655.63, representing a 9.84% increase in loss year-over-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥2,576,218.08, an increase in loss of 29.08% compared to the previous year[5]. - The basic and diluted earnings per share were both -¥0.0056, reflecting an 11.11% improvement in loss compared to the same period last year[5]. - Total operating revenue for the current period was ¥228,414,862.64, a slight decrease from ¥228,744,341.01 in the previous period, representing a decline of approximately 0.14%[18]. - Net profit for the current period was a loss of ¥11,571,407.58, compared to a profit of ¥14,027,447.67 in the previous period, indicating a significant decline[19]. Assets and Liabilities - Total assets at the end of the reporting period were ¥925,406,528.97, a decrease of 0.83% from the end of the previous year[5]. - The company's total assets decreased to ¥925,406,528.97 from ¥933,166,569.41, reflecting a reduction of approximately 0.8%[17]. - Current assets increased to ¥534,992,432.67 from ¥515,196,124.27, showing a growth of about 3.5%[16]. - The company's total liabilities rose to ¥173,199,761.72 from ¥166,415,829.70, an increase of approximately 4.7%[17]. - The company's total equity attributable to shareholders decreased by 2.11% to ¥748,207,707.63 compared to the end of the previous year[5]. - The company's total equity decreased to ¥752,206,767.25 from ¥766,750,739.71, a decline of about 1.9%[18]. Cash Flow - The company's cash flow from operating activities showed a net outflow of -¥1,820,451.14, which is an improvement of 85.25% compared to the previous year[5]. - The net cash flow from operating activities improved by 85.25%, reaching -1,820,451.14, attributed to reduced cash payments for purchasing Chinese medicinal materials and increased collections from accounts receivable[9]. - Cash inflow from operating activities totaled 246,300,713.20 CNY, an increase from 229,823,388.87 CNY in the previous period, representing an increase of approximately 7.5%[20]. - Cash outflow from operating activities was 248,121,164.34 CNY, compared to 242,164,560.28 CNY in the previous period, resulting in a net cash flow from operating activities of -1,820,451.14 CNY, an improvement from -12,341,171.41 CNY[20]. - The net cash flow from investing activities decreased by 172.00%, totaling -10,584,071.39, primarily due to a reduction in the scale of redeeming financial products[9]. - Cash inflow from investment activities was 113,220,646.68 CNY, down from 161,551,091.36 CNY in the previous period, a decrease of approximately 29.9%[21]. - Cash outflow from investment activities totaled 123,804,718.07 CNY, compared to 146,850,820.49 CNY in the previous period, leading to a net cash flow from investment activities of -10,584,071.39 CNY, a decline from 14,700,270.87 CNY[21]. - The net cash flow from financing activities improved by 62.47%, amounting to -5,108,269.87, mainly due to decreased dividend distribution expenses[9]. - Cash inflow from financing activities was 5,170,000.00 CNY, an increase from 3,400,000.00 CNY in the previous period, representing a growth of approximately 52.2%[21]. - Cash outflow from financing activities was 10,278,269.87 CNY, down from 17,010,060.96 CNY in the previous period, resulting in a net cash flow from financing activities of -5,108,269.87 CNY, an improvement from -13,610,060.96 CNY[21]. Investments and Business Activities - The company established a new health management company with a registered capital of RMB 1 million, holding a 19% stake, focusing on health diagnosis services[13]. - The company formed a joint venture for ophthalmic diagnosis services with a registered capital of RMB 2 million, also holding a 19% stake[13]. - The company transferred 100% equity of Jiangxi Yuanqifu Pharmacy Chain Co., Ltd. for RMB 750,000, which will no longer be included in the consolidated financial statements[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,433[11]. - The largest shareholder, Guangdong Jino Health Technology Co., Ltd., holds 45.00% of the shares, amounting to 72,000,000 shares[11]. Expenses and Financial Management - Financial expenses increased by 162.77% to ¥987,915.22 due to new business expansion and increased rental costs[8]. - Investment income decreased by 55.49% to ¥3,728,443.65, primarily due to reduced idle funds available for investment and losses from joint ventures[8]. - The fair value change income decreased by 70.51%, amounting to 461,965.43, primarily due to reduced idle funds available for financial management as the company expanded new businesses[9]. - Credit impairment losses increased by 122.28%, totaling -291,888.35, mainly due to an increase in accounts receivable leading to higher bad debt provisions[9]. - Research and development expenses for the current period were ¥6,675,637.43, slightly up from ¥6,416,666.62 in the previous period[18]. Audit Information - The company did not undergo an audit for the third quarter financial report[22].